BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS
BIOS was delisted on the 6th of October, 2023.
57 hedge funds and large institutions have $179M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$15.2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$11.7M |
| 3 |
LA
Linden Advisors
New York
|
+$9.87M |
| 4 |
Millennium Management
New York
|
+$9.77M |
| 5 |
Goldman Sachs
New York
|
+$8.14M |
Top Sellers
BIOS Hedge Fund Activity: Q1 2022 in Review
57 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q1 2022, worth a combined $179M.
Buyers outnumbered sellers: 57 funds opened new BIOS positions and 0 closed out — a net gain of 57 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Saba Capital Management, opening a new position worth an estimated $15.2M.
- 57 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $179M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q1 2022.
- 57 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q1 2022 and 0 closed out, a net change of +57 holders.
- The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q1 2022 was Saba Capital Management, an estimated $15.2M added.
Based on aggregated 13F filings for Q1 2022.